ArticleCancer research2025

Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.

Kristina Drizyte-Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.